CHITA – a registry of in vitro NAMs
Kudos to the GSRC team at the FDA and NCATS for progress on the Global Substance Registration System. Updates were shared at a recent GSRS User Group Conference, hosted at the University of…
Check out the thoughtful and comprehensive review of AI in drug discovery by Andreas Bender and Isidro Cortés-Ciriano, Artificial intelligence in drug discovery: what is realistic, what are illusions? Part…
In ADDC’s “Things I Wish I Knew” webinar series, we’ve been learning from prominent scientists, entrepreneurs, and investors about their successes, struggles, and the things they wished they knew before…
We’ve all been there. When reading a paper with interesting results, questions arise about some detail of the experiment. We go to the methods section for a quick check, only…
Researchers are using phenotypic assays at earlier and earlier stages of drug discovery. Assays for use in hit triage must be exceptional. In a previous post we’ve described the impact…
Quietly happening beneath the radar, phenotypic platforms are becoming integrated into drug discovery processes. Why this is happening and how are phenotypic assays transforming the stages of drug discovery? Multiple…
It takes courage to address common pitfalls in drug discovery and perseverance to traverse the route. In my work and as an advisor I’ve seen 100s of early-stage drug discovery…
How can we incorporate human-based animal alternatives into drug discovery? Can we reduce animal testing and still improve program success? Making good decisions requires integrating information from many assays and…
A strong chain of translatability is crucial for successful drug discovery programs. The chain of translatability is a molecular-level association between the mechanisms that drive the assay phenotype, the preclinical disease…
It’s not just about measuring what matters – it’s about making what you measure matter. There are many options for endpoints to measure in phenotypic assays. Endpoints to consider include…
